| Methods | Number of sites unknown Randomization: Identical packaging Patients blinded; providers blinded |
|
| Participants | Geographic region: Italy Study setting: community N = 60 Baseline IPSS: NA Baseline prostate volume: NA Mean age: NA Age range: 50 to 80 Race: White Diagnostic criteria: Men with symptomatic BPH confirmed on rectal examination |
|
| Interventions | Control 1: matching placebo Control 2: Pygeum africanum extract Treatment: Permixon® 320 mg daily Study duration: 4 weeks Lost to follow up: unclear |
|
| Outcomes | Patient self-rating Dysuria (pain on voiding) Urgency Tenesmus Difficult urination Post-voiding residue Pollachiuria Nocturia Dropouts due to side effects: none |
|
| Notes | Exclusions: Details not given | |
| Risk of bias | ||
| Item | Authors’ judgement | Description |
| Adequate sequence generation? | Unclear | B |
| Allocation concealment? | Unclear | B |
| Blinding? All outcomes |
Yes | A - Adequate |
| Incomplete outcome data addressed? All outcomes |
Yes | A - Adequate |
| Free of selective reporting? | Yes | A - Adequate |
| Free of other bias? | Yes | A - Adequate |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.